eXmoor pharma concepts ltd

eXmoor pharma concepts ltd is a UK-based company specializing in cell and gene therapy solutions, offering services that encompass consulting, process development, and GMP manufacturing to support biotech and academic clients in therapy development. Founded in 2004 in Bristol, UK, eXmoor pharma concepts ltd focuses on providing comprehensive services in the cell and gene therapy sector. The company was co-founded by Angela Osborne, who also serves as CEO. eXmoor has completed 2 deals, with the most recent occurring on May 30, 2023, when it raised USD 35 mn in Series A funding co-led by Kineticos Ventures and MVM Partners, reaching a total amount raised of USD 35 mn.

eXmoor Pharma specializes in comprehensive end-to-end services within the cell and gene therapy sector, delivering an integrated suite that includes consulting, process development, analytical services, GMP manufacturing, and facility design. Their offerings support over 170 clients, including biotech firms and academic institutions, in developing advanced therapies such as Viral Vectors, Autologous and Allogeneic Cell Therapies, and RNA technologies across Europe and North America. For the most recent financial year 2024, eXmoor Pharma reported a revenue amount of USD 6,008,551. 90.

The company also recorded an EBITDA amount of USD -6,376,030. 10 for the same period, indicating its operational performance during this timeframe. With the recent Series A funding raised on May 30, 2023, eXmoor pharma concepts ltd plans to utilize the USD 35 mn to launch its new manufacturing facility and enhance its capabilities in cell and gene therapy. The company aims to expand its services and reach into more geographic markets, particularly in Europe and North America, to better serve clients seeking innovative treatment solutions.